Venetoclax Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 10 mg, 50 mg, 100 mg
Reference Brands: Venclexta® (EU & US)
Category:
Oncology Cancer Care
Venetoclax Tablets (brand name Venclexta®) are oral BCL-2 inhibitors used for treating CLL, SLL, and AML. Available in 10 mg, 50 mg, and 100 mg strengths, they are manufactured under GMP standards and approved in US and EU markets, offering a reliable oncology solution.
Venetoclax is available in Tablet
and strengths such as 10 mg, 50 mg, 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Venetoclax is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Venetoclax can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Venetoclax Tablets are a targeted oral therapy used in the treatment of hematologic malignancies such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). As a potent BCL-2 inhibitor, Venetoclax promotes apoptosis in cancer cells by restoring programmed cell death pathways. Marketed under the brand name Venclexta®, it is available in 10 mg, 50 mg, and 100 mg strengths. Manufactured under GMP-certified facilities, Venetoclax offers a reliable oncology solution for B2B pharmaceutical partners across the US and EU, supporting effective cancer treatment strategies with proven clinical outcomes.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing